Milan

• A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended
  2024-514761-19-00 5 2023-01-25 Idiopathic Pulmonary Fibrosis
• A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk tran … Ended
  2023-503793-20-00 5 2023-01-18 Prevention of ischemic stroke in patients post acute non-cardioembolic
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 2) Ended
  2023-504238-23-00 5 2023-01-17 Hepatitis B, Chronic
• Phase 3 Study of Bepirovirsen in Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B (B-Well 1) Ended
  2023-504239-41-00 5 2023-01-09 Hepatitis B, Chronic
• An Open Label Study to Evaluate A3907 in Adults with Primary Sclerosing Cholangitis (PSC) Ended
  2022-500790-14-00 4 2023-01-02 Primary Sclerosing Cholangitis (PSC)
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 year … Ended
  2024-512095-35-00 9 2022-12-27 Relapsed or refractory neuroblastoma and other solid tumors (including
• Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp versus I … Ended
  2024-511755-18-00 5 2022-12-23 Invasive Candidiasis/ Candidemia
• Phase 2b Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Ended
  2024-514975-16-00 4 2022-12-22 Non-infectious, Intermediate-, Posterior- or Pan-uveitis
• An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2) Ended
  2024-515185-13-00 5 2022-12-21 geographic atrophy
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant … Ended
  2023-509078-45-00 4 2022-12-19 Multiple sclerosis
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended
  2023-508528-36-00 5 2022-12-16 Resected squamous cell carcinoma of the head and neck
• A Phase IIa Study to assess Safety, Tolerability, and Pharmacodynamics of AZD4831 in Adult Participants with Non-cirrhotic NASH with Fibrosi … Ended
  2022-500594-13-00 4 2022-12-14 "Non-Alcoholic Steatohepatatis (NASH) is the progressive form of Non-A
• Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy … Ended
  2024-512621-88-00 4 2022-12-06 Acute Respiratory Distress Syndrome
• A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended
  2023-505645-12-00 4 2022-11-28 Parkinson's Disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis … Ended
  2023-503794-38-00 5 2022-11-24 Prevention of stroke or systemic embolism in atrial fibrillation
• A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody Dru … Ended
  2024-513708-33-00 1 2022-11-23 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended
  2023-509876-40-00 4 2022-11-22 Multiple System Atrophy
• Caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immune-mediated thrombotic thrombo … Ended
  2024-513262-19-00 5 2022-11-21 Thrombotic Thrombocytopenic Purpura
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S … Ended
  2024-511610-20-00 4 2022-11-08 Alzheimer's Disease
• A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended
  2022-500350-42-01 10 2022-11-07 Prevention of RSV
• Study to Evaluate the Safety and Efficacy of Linsitinib in Patients with Active, Moderate to Severe Thyroid Eye Disease Ended
  2024-514449-12-00 4 2022-11-04 Disease (TED)

Showing 2,089–2,112 of 2,361 trials